Clinical Trials
49 trialsNCT07222566 2026-06-04
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
Phase 3 Recruiting
NCT07227402 2026-06-04
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05043090 2026-05-22
SAMETA
AstraZeneca
Phase 3 Active not recruiting
NCT06312137 2026-05-22
TroFuse-019
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06417814 2026-05-14
TROPION-Lung15
AstraZeneca
Phase 3 Recruiting
NCT06758401 2026-04-20
Be6A Lung-02
Pfizer
Phase 3 Recruiting
NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT05261399 2026-04-06
SAFFRON
AstraZeneca
Phase 3 Active not recruiting
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT03976323 2026-02-25
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03755791 2025-12-11
COSMIC-312
Exelixis
Phase 3 Active not recruiting
NCT03703297 2025-11-21
ADRIATIC
AstraZeneca
Phase 3 Active not recruiting
NCT03519971 2025-10-28
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT04035486 2025-10-10
FLAURA2
AstraZeneca
Phase 3 Active not recruiting
NCT00532155 2025-09-10
VITAL
Sanofi
Phase 3 Completed
NCT03937219 2025-09-10
COSMIC-313
Exelixis
Phase 3 Active not recruiting
NCT03800134 2025-06-11
AEGEAN
AstraZeneca
Phase 3 Active not recruiting
NCT01345084 2025-03-28
NICAP
Eurofarma Laboratorios S.A.
Phase 3 Withdrawn
NCT00051545 2025-02-25
Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma
LEO Pharma
Phase 3 Terminated
NCT02112656 2024-08-20
OPTIMA
Imunon
Phase 3 Completed
NCT04816214 2024-03-05
GEOMETRY-E
Novartis
Phase 3 Terminated
NCT03626545 2023-08-21
CANOPY-2
Novartis
Phase 3 Terminated
NCT03952403 2023-08-08
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shanghai Henlius Biotech
Phase 3 Unknown
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT00198315 2022-03-04
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
Inovio Pharmaceuticals
Phase 3 Terminated
NCT00198328 2022-03-04
Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma
Inovio Pharmaceuticals
Phase 3 Terminated
NCT02737501 2021-08-20
ALTA-1L
Takeda
Phase 3 Completed
NCT02367781 2021-08-09
IMpower130
Hoffmann-La Roche
Phase 3 Completed
NCT01755767 2021-04-06
METIV-HCC
Daiichi Sankyo
Phase 3 Completed
NCT02793128 2020-12-22
Olympus
UroGen Pharma Ltd.
Phase 3 Completed
NCT00216372 2020-11-05
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
Ipsen
Phase 3 Completed
NCT04006691 2020-05-07
Retreatment
UroGen Pharma Ltd.
Phase 3 Withdrawn
NCT00968968 2019-06-10
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Phase 3 Terminated
NCT03717038 2019-02-04
Sym004 Versus TAS-102 in Patients With mCRC
Symphogen A/S
Phase 3 Withdrawn
NCT00838201 2018-10-18
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Amgen
Phase 3 Completed
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated
NCT01035229 2016-09-22
EVOLVE-1
Novartis
Phase 3 Completed
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00863746 2015-01-19
MISSION
Bayer
Phase 3 Completed
NCT00412061 2014-11-21
RADIANT-2
Novartis
Phase 3 Completed
NCT01166542 2014-11-05
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Oncolytics Biotech
Phase 3 Completed
NCT00673049 2013-07-24
NSCLC
Pfizer
Phase 3 Terminated
NCT00034879 2013-01-04
Iressa Expanded Access Program (EAP)
AstraZeneca
Phase 3 Completed
NCT00822809 2012-10-03
CASIMAS
Neovii Biotech
Phase 3 Completed
NCT01009593 2012-09-10
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Phase 3 Terminated
NCT00364455 2010-04-27
Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.
Janssen-Ortho Inc., Canada
Phase 3 Completed
NCT00050388 2008-06-24
Phase II Trial of Allovectin-7® for Head and Neck Cancer
Vical
Phase 3 Completed
NCT00047632 2007-11-01
Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer
InterMune
Phase 3 Terminated